Increase in survival due to metformin and metformin-analogues has also been reported in transgenic ErbB2/neu mice [14–16], implying that add-on insulin sensitizers may improve survival of non-diabetic ErbB2 breast cancer. Here, INS is linked to breast carcinoma.